Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy

Table 2 Univariate and multivariate analyses of OS

Characteristic	Univariate			Multivariate
Characteristic	HR	95% CI	p value	HR	95% CI	p value
Age (≥ 65 vs. < 65)	1.104	0.830–1.467	0.497
Sex (male vs. female)	1.183	0.858–1.632	0.305
Smoking (yes vs. no)	1.080	0.816–1.428	0.590
Alcohol (yes vs. no)	1.372	1.036–1.817	0.027
BMI (≥ 24 vs. < 24)	0.750	0.552–1.017	0.064
NRI (≥ 100 vs. < 100)	0.610	0.426–0.874	0.007
Anemia (yes vs. no)	1.439	1.073–1.928	0.015
Albumin (≥ 40 vs. < 40)	0.582	0.416–0.813	0.002	0.658	0.470–0.923	0.023
Sarcopenia (yes vs. no)	1.457	1.024–2.074	0.036	1.638	1.113–2.410	0.016
TATI (> 83.0 vs. ≤ 83.0)	0.689	0.520–0.913	0.010
SATI (> 27.8 vs. ≤ 27.8)	0.707	0.533–0.937	0.016
VATI (> 49.0 vs. ≤ 49.0)	0.659	0.497–0.872	0.004
Location (middle/lower vs. neck/upper)	1.698	1.203–2.125	0.001
Length (≤ 4 vs. > 4)	1.054	0.797–1.394	0.710
Treatment (CRT vs. RT)	0.275	0.615–1.148	0.841
RT dose (≤ 60 vs. > 60)	1.136	0.854–1.512	0.382
TNM stage (III–IV vs. I–II)	1.421	1.226–1.647	< 0.001	2.439	1.710–3.228	< 0.0001
T stage (T3–4 vs. T1–2)	1.291	1.084–1.539	0.004
N stage (N2–3 vs. N0–1)	1.501	1.120–2.013	0.007	2.070	1.124–3.817	< 0.0001

HR hazard ratio, CI confidence interval, p values highlighted in bold indicated p < 0.05

ISSN: 1471-230X